NCT02875340已完成2 期
A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen
ValiSeek Limited0 个研究点目标入组 8 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
The objectives of this study are to assess the safety, tolerability, pharmacokinetics and efficacy of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.
详细描述
This is a Phase II, open label study to assess the efficacy, safety and tolerability of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma after failure of at least one prior chemotherapeutic regimen. Eligible patients will be enrolled as a single cohort and treated with VAL401, given as oral capsules. VAL401 is a formulation of Risperidone (active pharmaceutical ingredient) in a liquid lipid filled capsule.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed diagnosis of Stage IIIB or Stage IV adenocarcinoma of the lung. Patients with mixed histology will be eligible if adenocarcinoma is the predominant histology.
- •Measurable disease according to RECIST version 1.
- •Prior chemotherapy for relapsed or metastatic non small cell lung cancer.
- •Life expectancy of at least 3 months.
- •Negative human chorionic gonadotropin (hCG) test in women of childbearing potential (defined as women ≤ 50 years of age or history of amenorrhea for ≤ 12 months prior to study screening). Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control e.g. barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices, during the entire duration of the study and for 1 month after the final administration of VAL
- •Note that female patients may be surgically sterile (with appropriate documentation in the patient's medical records).
- •Ability to give written, informed consent prior to any study-specific screening procedures with the understanding that the consent may be withdrawn by the patient at any time without prejudice.
- •Patient is capable of understanding the protocol requirements, is willing and able to comply with the study protocol procedures, and has signed the informed consent document.
排除标准
- •Radiotherapy or surgery (other than biopsy) within 4 weeks prior to Cycle 1 Day
- •Any chemotherapy regimens (including investigational agents) with delayed toxicity with 6 weeks of Cycle 1 Day 1, or received any chemotherapy regimens given continuously or on a weekly basis which have limited potential for delayed toxicity within 2 weeks prior to Cycle 1 Day
- •Palliative treatment regimens, and other concomitant drugs regimens are permitted with stable toxicity, and recording of all concomitant medications (including herbal).
- •Pregnant or lactating female patients.
- •Active hepatitis B or C or other active liver disease (other than malignancy).
- •Any active, clinically significant, viral, bacterial, or systemic fungal infection within 2 weeks prior to Cycle 1 Day 1; other than cytomegalovirus which may be present providing any required concomitant anti-viral treatment is recorded appropriately.
- •Known human immunodeficiency virus positivity.
- •History of clinically significant cardiac condition, including ischemic cardiac event, myocardial infarction or unstable cardiac disease with 3 months prior to Cycle 1 Day
- •Active brain metastases (defined as stable for <4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids and/or leptomeningeal disease).
- •Any known contraindications to Risperidone or patients who would not be eligible to receive the treatment as defined in the Special Warnings and Precautions section of the local label for Risperidone.
- •Any medical history that in the Investigator's opinion would jeopardise compliance with the protocol.
研究组 & 干预措施
VAL401 treatment
Experimental
Patients received VAL401 oral formulation once daily according to their level of tolerance (2 mg - 10 mg).
干预措施: VAL401 (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: 6 months
PFS is defined as the time from screening to disease progression (or death if the patient died before progression), with progression date nominally defined as the date the patient was withdrawn from the trial, where the Principal Investigator has determined by their professional discretion the patient has symptomatic disease progression.
次要结局
- Patient Quality of Life During VAL401 Treatment(6 months)
- Number of Participants Reporting Adverse Events and Serious Adverse Events(6 months)
- Peak Plasma Concentration (Cmax)(1 Day and 2 weeks)
- Trough Plasma Concentration (Cmin)(1 Day and 2 weeks)
- Overall Survival(6 months)
- Number of Patients With Disease Control(6 months)
- Plasma VAL401 Half-life (t 1/2)(1 Day and 2 weeks)
研究者
相似试验
招募中
1 期
To Evaluate KC1036 in the Patients with Advanced Digestive System TumorsDigestive System TumorsNCT05260385Beijing Konruns Pharmaceutical Co., Ltd.133
终止
2 期
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.Advanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction CarcinomaNCT05188209Lepu Biopharma Co., Ltd.6
招募中
2 期
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GIgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) GlomerulopathyNCT06419205Akebia Therapeutics30
招募中
2 期
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric CancerNCT06219941AstraZeneca226
已完成
1 期
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)Solid TumorsHead and Neck CancerUC (Urothelial Cancer)Lung CancerNCT02318277Incyte Corporation176